Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death

References

• LehmannSRavnACarlssonLContinuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia RegistryLeukemia20112571128113421502956
   PubMed Web of Science ®Google Scholar
• McClellanJSKohrtHECoutreSTreatment advances have not improved the early death rate in acute promyelocytic leukemiaHaematologica201297113313621993679
   PubMed Web of Science ®Google Scholar
• RashidiAGoudarRKSayedianFAll-trans retinoic acid and early mortality in acute promyelocytic leukemiaLeuk Res201337101391139223906626
   PubMed Web of Science ®Google Scholar
• KimDYLeeJHLeeJHSignificance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemiaLeuk Res201135215215820554322
   PubMed Web of Science ®Google Scholar
• JácomoRHMeloRASoutoFRClinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclinesHaematologica200792101431143218024380
   PubMed Web of Science ®Google Scholar
• ParkJHQiaoBPanageasKSEarly death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidBlood201111851248125421653939
   PubMed Web of Science ®Google Scholar
• de la SernaJMontesinosPVellengaECauses and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicinBlood200811173395340218195095
   PubMed Web of Science ®Google Scholar
• HeBHuSQiuGGuWClinical characteristics of acute promyelocytic leukemia manifesting as early deathMol Clin Oncol20131590891024649269
   PubMedGoogle Scholar
• GhavamzadehAAlimoghaddamKRostamiSPhase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemiaJ Clin Oncol201129202753275721646615
   PubMed Web of Science ®Google Scholar
• Di BonaEAvvisatiGCastamanGEarly haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemiaBr J Haematol2000108468969510792270
   PubMed Web of Science ®Google Scholar
• TestaULo-CocoFPrognostic factors in acute promyelocytic leukemia: strategies to define high-risk patientsAnn Hematol201695567368026920716
   PubMed Web of Science ®Google Scholar
• KrugURölligCKoschmiederAComplete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesLancet201037697572000200821131036
   PubMed Web of Science ®Google Scholar
• WalterRBOthusMBorthakurGPrediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentJ Clin Oncol201129334417442321969499
   PubMed Web of Science ®Google Scholar
• JeddiRGhédiraHBen AmorRTreatment of acute promyelocytic leukemia with AIDA based regimen. Update of a Tunisian Single Center StudyMediterr J Hematol Infect Dis201131e201103322084648
   PubMedGoogle Scholar
• JeddiRGhédiraHMenifSTreatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experienceHematology201015420420920670478
   PubMed Web of Science ®Google Scholar
• LouYMaYSuoSPrognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapyLeuk Res201539993894426183877
   PubMed Web of Science ®Google Scholar
• PosadaDBuckleyTRModel selection and model averaging in phylogenetics: advantages of Akaike information criterion and Bayesian approaches over likelihood ratio testsSyst Biol200453579380815545256
   PubMed Web of Science ®Google Scholar
• SteyerbergEWVickersAJCookNRAssessing the performance of prediction models: a framework for traditional and novel measuresEpidemiology201021112813820010215
   PubMed Web of Science ®Google Scholar
• RashidiARileyMGoldinTADelay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United StatesLeuk Res20143891036104025035073
   PubMed Web of Science ®Google Scholar
• MitrovicMSuvajdzicNBogdanovicAInternational Society of Thrombosis and Hemostasis Scoring System for disseminated intra-vascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemiaMed Oncol201330147823371042
   PubMed Web of Science ®Google Scholar
• ShenZXChenGQNiJHUse of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patientsBlood1997899335433609129042
   PubMed Web of Science ®Google Scholar
• NiuCYanHYuTStudies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patientsBlood199994103315332410552940
   PubMed Web of Science ®Google Scholar
• SoignetSLMaslakPWangZGComplete remission after treatment of acute promyelocytic leukemia with arsenic trioxideN Engl J Med199833919134113489801394
   PubMed Web of Science ®Google Scholar
• ThomasXPigneuxARaffouxEHuguetFCaillotDFenauxPSuperiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemiaHaematologica200691799699716757416
   PubMed Web of Science ®Google Scholar
• SoignetSLFrankelSRDouerDUnited States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaJ Clin Oncol200119183852386011559723
   PubMed Web of Science ®Google Scholar
• FoxERazzoukBIWidemannBCPhase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphomaBlood2008111256657317959855
   PubMed Web of Science ®Google Scholar